Monotherapy for continued treatment of locally advanced/metastatic non-small cell lung cancer after failure of both platinum-based & docetaxel chemotherapies.
250 mg daily. Patient w/ poorly tolerated diarrhea or skin adverse drug reactions Brief therapy interruption up to 14 days followed by reinstatement of 250 mg daily. Patient receiving potent CYP3A4 inducer eg, rifampicin or phenytoin Consider increasing the dose to 500 mg daily.
Pulmonary toxicity. Hepatotoxicity; consider periodic liver function testing. Hepatic & severe renal impairment. Pregnancy & lactation. Not indicated for use in childn.
Increased exposure of metoprolol. Reduced mean AUC w/ rifampicin; high doses of ranitidine w/ Na bicarbonate. Increased mean AUC w/ itraconazole. INR elevations &/or bleeding events w/ warfarin.
Sign Out
